Biomarkers would seem to have it all – they could save money for the health care system by saving patients ineffective care and its attendant toxicity risks. But considering how useful they are, there are a surprisingly low number of biomarkers in widespread clinical use. "The way it's been going for the last 30 years has resulted in very few validated biomarkers," Dan Hayes told BioWorld Insight. Read More
Biopharma deal-making returned to the fore during the first half of 2013, with 368 licenses and joint ventures (JV) compared to 265 during the first six months of 2012 – a 39 percent surge, according to Thomson Reuters Recap. All told, Recap captured 1,234 life science deals during the first half of the year, with licenses and JVs representing 30 percent of the total. Read More
